OMass Therapeutics Pivots From Services To Drug Discovery With Novel Mass Spect Technology

 
• By John Davis

The UK start-up has quickly switched from research services to drug discovery to exploit more fully its novel platform technology for drug screening and development, funded by Syncona and other investors.  

Tracks
Changing Track • Source: Shutterstock

More from Start-Ups & SMEs

More from Business